-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CGsrxwFrIQGZU50oDmRYuxYBk+hqnBHDUg/cdaa+GJb7d6F/8YqAmdX2CCNpLs/1 EE+YuF2dNvlBeJsagDyuCw== 0001104659-05-017048.txt : 20060421 0001104659-05-017048.hdr.sgml : 20060421 20050419153543 ACCESSION NUMBER: 0001104659-05-017048 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEORX CORP CENTRAL INDEX KEY: 0000755806 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911261311 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 300 ELLIOTT AVENUE WEST STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98119-4114 BUSINESS PHONE: 2062817001 MAIL ADDRESS: STREET 1: 300 ELLIOTT AVENUE WEST STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98119-4114 CORRESP 1 filename1.htm

 

April 19, 2005

 

U.S. Securities and Exchange Commission
Division of Corporate Finance, Mail Stop 3-9
450 Fifth Street, N.W.

Washington, D.C. 20549

 

Re:                             NeoRx Corporation
Preliminary Proxy Statement on Schedule 14A
Filed April 11, 2005
File No.  0-16614

 

Ladies and Gentlemen:

 

In connection with NeoRx Corporation’s response to the Staff’s comments on the above referenced filing, which response separately has been provided via submission of a detailed cover letter and filing of Amendment No. 1 to Schedule 14A with the Commission on April 19, 2005, the Company hereby acknowledges that:

 

•                  The Company is responsible for the adequacy and accuracy of the disclosures in the filing;

 

•                  Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

 

•                  The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

 

Very truly yours,

 

 

 

NEORX CORPORATION

 

 

 

s/Susan D. Berland

 

 

Susan D. Berland

 

Chief Financial Officer

 

 -----END PRIVACY-ENHANCED MESSAGE-----